HOT NEWS
Nycomed
NycomedNycomed is a privately owned pharmaceutical company that provides medicines for hospitals, specialists and general practitioners, as well as over-the-counter medicines in selected markets. The company is active in a range of therapeutic areas, focusing on gastroenterology, respiratory, inflammation, pain management, osteoporosis and surgical management. New products are sourced both from its own research and from business partners. Based in Europe, Nycomed is present in over 50 countries worldwide with increasing emphasis on fast-growing markets. The combined group employs 12,000 people. In 2007, it had annual sales of € 3.5 billion and an adjusted EBITDA of € 1.2 billion. For more information visit www.nycomed.com.

Nycomed RSS Channel

Title Filter     Display # 
# Article Title Hits
1 Global market launch of Daxas® (Roflumilast) kicks off in Germany 313
2 Nycomed's Daxas® (roflumilast) receives marketing authorisation in the European Union 1391
3 Nycomed's first quarter 2010 results confirm the direction 963
4 Nycomed's novel anti-inflammatory therapy Daxas® (roflumilast) recommended for approval in the European Union 1310
5 Nycomed on track in 2009 with strong growth in Key Products 1119
6 Nycomed sustains commitment to Russia-CIS and invests in new pharmaceutical production plant 1565
7 Nycomed reports sustained momentum in second quarter 2009 991
8 Nycomed to acquire local portfolio from Sanofi-Aventis and Zentiva 1390
9 Nycomed's Instanyl® is first intranasal fentanyl approved in Europe 2345
10 Nycomed receives Marketing Authorization for Pantoprazole 20mg OTC from European Commission 3008
11 Nycomed Reports a Solid Start to 2009 1015
12 Nycomed files European marketing authorisation application for Daxas® 1275
13 Nycomed's Instanyl® receives positive CHMP opinion 2320
14 Nycomed reports a satisfactory 2008 778
15 Nycomed and EffRx have announced a licensing agreement on drug for the treatment of osteoporosis 959
16 Nycomed optimises its European manufacturing network 687
17 Nycomed's preclinical anti-cancer program sold to Bayer Schering Pharma 778
 
Bookmark and Share